News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Constellation Pharmaceuticals Expands Leadership Team with Drug Development Industry Veterans



2/1/2011 8:44:14 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced the expansion of its leadership team with the appointment of Michael Cooper, M.D., as Chief Medical Officer and of Steven Paul, M.D., to the Board of Directors. Dr. Cooper was most recently Clinical Head of Oncology Translational Medicine at the Novartis Institutes for Biomedical Research, where his group contributed to the preclinical and clinical development of the Novartis oncology drug pipeline. Dr. Paul is Director of the Helen and Robert Appel Institute for Alzheimer’s Research at Weill Cornell Medical College and is the former President of Lilly Research Laboratories.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES